•Incyte's Monjuvi regimen reduced the risk of disease progression, relapse, or death by 25% compared to standard care in non-Hodgkin lymphoma patients.
•The study reported a higher rate of participant dropouts due to side effects associated with the multi-drug regimen.
•The CFTC has approved the integration of crypto perpetual futures into regulated U.S. markets, allowing platforms like Kalshi and Coinbase to offer them.
•The U.S. announced that persons are prohibited from receiving services from the Iranian government related to safe passage guarantees in the Strait of Hormuz.